ACUTE MYELOID LEUKEMIA

This study aims to find out if adults with acute myeloid leukemia (AML) who are considered less medically fit are willing to let a computer randomly assign them to either higher or lower intensity chemotherapy. The goal is to determine which treatment intensity works best for thi…

This early-stage study is testing whether adding very high doses of intravenous vitamin C to the standard two-drug treatment for acute myeloid leukemia (AML) is safe and more effective. It will enroll about 30 adults newly diagnosed with AML who are not healthy enough for intensi…

This study aims to find the best timing for giving extra donor immune cells to patients who have received a stem cell transplant for hard-to-treat blood cancers like leukemia. It will compare giving these cells as a preventive measure versus waiting and giving them only if early …

This study is for adults aged 60 or older with newly diagnosed acute myeloid leukemia (AML) who are less fit for intensive chemotherapy. It compares two treatment schedules combining the same three oral medications. The goal is to see if taking one of the drugs for 14 days per cy…

This early-stage trial aims to find a safe and effective dose of two oral drugs, olutasidenib and ziftomenib, used together. It is for adults with a hard-to-treat, relapsed form of acute myeloid leukemia (AML) that has two specific genetic mutations (NPM1 and IDH1). The study wil…

This study is testing if adding a drug called venetoclax to a stem cell transplant helps adults with acute myeloid leukemia (AML) stay in remission longer. Participants will receive either venetoclax or a placebo (inactive pill) before and after their transplant. The main goal is…

This study is testing if adding a new drug called olutasidenib to standard treatments helps patients with certain blood cancers. It is for adults newly diagnosed with Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS) who have a specific genetic change called an IDH1 …

This study is for adults with a type of blood cancer called acute myeloid leukemia (AML) who have a small amount of leftover cancer after initial treatment. The goal is to test if adding newer drugs to a standard chemotherapy is better at wiping out these hidden cancer cells befo…

This early-stage study is testing a new type of cell therapy called 'universal' CLL1 CAR-T for adults with acute myeloid leukemia (AML) that has come back or not responded to standard treatments. The therapy uses genetically modified immune cells designed to find and attack leuke…

This study is testing a new drug called pivekimab sunirine in children and teenagers whose acute myeloid leukemia (AML) has come back or hasn't responded to other treatments. The main goals are to check the drug's safety and see how it moves through the body. About 18 participant…

This study is not testing a new drug on people. Instead, it's using artificial intelligence (AI) to analyze past patient data. The goal is to see if a drug combination called VEN-DEC is better than standard chemotherapy for older adults (60-75) with a type of blood cancer called …

This is the first-ever study in people to test a new immune cell therapy for acute myeloid leukemia (AML), a serious blood cancer. Researchers will combine a patient's own specially trained immune cells with a vaccine and two standard drugs to see if the approach is safe and can …

This study is testing whether taking two oral medications, ivosidenib and azacitidine, can help keep a specific type of acute myeloid leukemia (AML) from coming back in older adults. It is for patients aged 55+ who have achieved remission after intensive chemotherapy and have a s…

This study is testing whether a drug called interferon-α can help prevent cancer from coming back in patients with high-risk forms of leukemia or myelodysplastic syndrome (MDS) who have just received a stem cell transplant. It will involve 100 patients aged 12-65 who have a speci…

This early-stage study aims to find a safe dose for a new three-drug combination to treat acute myeloid leukemia (AML). Researchers will add an experimental drug called eganelisib to two standard medications to see if it's safe and shows early signs of helping patients. The study…

This study is testing an oral medication called ziftomenib for adults with a specific type of acute myeloid leukemia (AML) who are not healthy enough for standard intensive chemotherapy. The drug works by blocking a specific pathway (the menin pathway) that these leukemia cells n…

This early-stage study is testing a new two-drug combination (lonitoclax and azacitidine) for adults whose acute myeloid leukemia has returned or hasn't responded to prior treatments. The main goals are to find a safe and effective dose and to see how well the body handles the dr…

This study is testing a new treatment approach for adults with acute myeloid leukemia (AML) that has returned or not responded to standard therapies. It combines a targeted radiation drug with chemotherapy and low-dose whole-body radiation to prepare patients for a stem cell tran…

This is a first-in-human study to see if a new type of donor cell treatment is safe and might work better than the standard. The new treatment uses immune cells collected from a related donor after they exercise, with the idea that exercise makes these 'natural killer' cells more…

This trial is testing a new type of stem cell transplant for young adults (under 55) with a very high-risk form of acute myeloid leukemia (AML) that hasn't responded well to standard chemotherapy. The treatment uses umbilical cord blood stem cells and adds extra infusions of a ty…

This study is testing if adding a new drug called bleximenib to standard chemotherapy works better than chemotherapy alone for adults newly diagnosed with specific genetic types of acute myeloid leukemia (AML). About 875 participants will receive standard chemo plus either blexim…

This study is for adults with a high-risk type of acute myeloid leukemia (AML) who are in remission and planning a stem cell transplant. It compares two different treatments given before the transplant to help keep the cancer from coming back. One treatment uses a newer drug comb…

This study is testing a new drug, BL-M11D1, in combination with two different sets of standard chemotherapy drugs for adults newly diagnosed with acute myeloid leukemia (AML). The main goals are to find a safe and effective dose and to see how well the combinations work to contro…

This study is testing if a shorter course of a common leukemia drug combination is as effective as the standard longer course for older or frail patients. Researchers want to see if stopping the drug early for patients who respond quickly can reduce severe side effects like infec…

This study is testing whether special dental wipes containing xylitol, a natural sugar, can prevent serious bloodstream infections in children and young adults being treated for acute myeloid leukemia (AML). Chemotherapy weakens the immune system, making patients vulnerable to in…

This study aims to see if adding hypnosis or virtual reality sessions to standard hospital care can help reduce anxiety and stress for adults newly diagnosed with a serious blood cancer (acute myeloid leukemia). Participants will be randomly assigned to receive either standard ca…

This is a small, early-stage study to see if a single injection of a drug called motixafortide can help doctors find very small amounts of leftover leukemia cells in the blood. The study involves adults with acute myeloid leukemia (AML) who are in remission after initial chemothe…

This study aims to create and test a structured follow-up system for children and young adults who have survived blood cancers like leukemia and lymphoma. It will track 400 survivors for three years to understand the long-term health problems they face and see if a new, organized…

This study aims to understand how blood clotting changes in adults newly diagnosed with a fast-growing blood cancer called acute myeloid leukemia (AML). Researchers will observe 80 patients, checking their blood's ability to clot before and after they receive a standard, strong c…